Current market catalysts

GRFS or SDZNY: Which Is the Better Value Stock Right Now?

In a comparison of two medical-drugs stocks, Grifols (GRFS) emerges as the superior value option over Sandoz Group AG Sponsored ADR (SDZNY). GRFS has a stronger Zacks Rank of #2 (Buy) versus SDZNY's #3 (Hold), along with significantly better valuation metrics including a forward P/E of 7.03 compared to SDZNY's 20.54, a PEG ratio of 0.28 versus 1.77, and a P/B ratio of 0.57 versus 3.95. GRFS earned a Value grade of A while SDZNY received a C.

Argan's Q2 Beat Shows Power Strength as Industrial Margins Stay Soft

Argan, Inc. (AGX) reported strong Q2 fiscal 2027 results with earnings up 50.4% and revenue up 61.5%, beating consensus estimates. The Power segment drove margin strength with a 52.9% revenue increase and improved gross margins to 22.4%. However, Industrial revenues doubled but margins fell to 7.3% due to worsening project completion estimates. Management expects Industrial margins to remain below historical norms for another 1-2 quarters.

SSRM Advances With Marigold Growth Initiatives: Can They Aid Upside?

SSR Mining Inc. (SSRM) is advancing growth initiatives at its Marigold mine in Nevada, including the Buffalo Valley project, with an updated life-of-mine plan expected by end of 2026. The company expects 2026 Marigold production of 170,000-200,000 ounces, heavily weighted to Q4 with higher grades driving output. SSRM increased 2026 growth capital guidance from $48M to $65M and continues exploration at brownfield targets. The stock trades at a forward P/E of 9.55x, below industry average, with 2026 earnings consensus of $3.87/share (+92.5% YoY), though recent estimates have declined.

Is Argan Worth Buying as Growth Surges but Valuation Stays Elevated?

Argan Inc. reported 56.5% revenue growth and $126.5 million adjusted EBITDA in fiscal 2027's first half, supported by a $2.5 billion backlog. However, the company faces margin pressure with gross margins declining from 25% to 19.3%, and trades at a premium 31.1X forward earnings. While growth signals remain favorable, execution risks and uncertain project timing present challenges to justify the current valuation.

How Carlyle's Wealth Push Opens New Avenues for Fee Revenue Growth

The Carlyle Group is expanding its wealth-management business through strategic acquisitions and partnerships to increase private-market access for advisors and high-net-worth clients. The company acquired MAI Capital Management and Intelliflo, and partnered with SEI and UBS to strengthen its wealth platform. Carlyle targets $2.8 billion in management fees by 2028, up from $2.2 billion in 2025, with wealth and retirement expected to account for 20% of over $200 billion in targeted inflows.

PAX vs. KKR: Which Stock Is the Better Value Option?

A comparison of two Financial - Investment Management stocks reveals that Patria Investments (PAX) presents a better value opportunity than KKR & Co. Inc. (KKR). PAX holds a Zacks Rank #2 (Buy) with a forward P/E of 8.10 and Value grade of A, while KKR has a Zacks Rank #3 (Hold) with a forward P/E of 16.49 and Value grade of D. PAX demonstrates stronger earnings estimate revisions and more attractive valuation metrics across multiple indicators.

WaFd's EverBank Merger Deal: A Boost to Earnings & Scale?

WaFd, Inc. announced a planned merger with EverBank Financial Corp, expected to close in early 2027. The deal is projected to deliver 29% EPS accretion in 2027, improve funding stability through combined deposit bases, and expand commercial banking and wealth management capabilities. The combined company will be renamed EverBank Financial Corp with legacy EverBank investors owning 59.2% and WaFd shareholders holding 40.8%.

HAYW or MAIR: Which Is the Better Value Stock Right Now?

In a comparison of two Electronics - Miscellaneous Products stocks, Hayward Holdings (HAYW) and Madison Air Solutions (MAIR), both holding a Zacks Rank #2 (Buy), HAYW emerges as the superior value option. HAYW has a lower forward P/E ratio of 16.00 compared to MAIR's 23.40, a better P/B ratio of 1.84 versus 3.56, and earns a Value grade of B compared to MAIR's C grade.

SSUMY vs. CSL: Which Stock Is the Better Value Option?

In a comparison of two Diversified Operations sector stocks, Sumitomo Corp. (SSUMY) emerges as the superior value opportunity compared to Carlisle (CSL). SSUMY holds a Zacks Rank #1 (Strong Buy) with a forward P/E of 7.95 and Value grade of A, while CSL has a Zacks Rank #3 (Hold) with a forward P/E of 16.55 and Value grade of C. SSUMY's stronger earnings outlook and more attractive valuation metrics make it the better choice for value investors.

Here's Why You Should Retain AMN Stock in Your Portfolio for Now

AMN Healthcare Services expects Q3 nurse and allied staffing revenues to grow 9-11% driven by strong healthcare demand and expanding Managed Services Programs (MSPs) which now represent 46% of consolidated revenues. The company is diversifying through AI-enabled platforms and recent acquisitions. However, competitive pressures, declining language services revenues, and regulatory challenges pose risks to growth.

WF or CM: Which Is the Better Value Stock Right Now?

A comparison of two foreign banks shows Woori Bank (WF) presents a better value opportunity than Canadian Imperial Bank (CM). Woori Bank has a Zacks Rank of #2 (Buy) with a forward P/E of 8.32 and Value grade of B, while Canadian Imperial Bank has a Zacks Rank of #3 (Hold) with a forward P/E of 15.85 and Value grade of D. Woori Bank's lower valuation metrics and positive earnings revision trends make it the more attractive option for value investors.

PECO or REG: Which Is the Better Value Stock Right Now?

Phillips Edison & Company (PECO) presents a better value opportunity than Regency Centers (REG) based on Zacks Rank and Style Scores analysis. PECO holds a #2 Buy rating with a Value grade of B, while REG has a #3 Hold rating with a Value grade of D. PECO's forward P/E of 14.07 and PEG ratio of 2.02 are more favorable than REG's forward P/E of 15.49 and PEG ratio of 4.47.

PACS Expands Florida Footprint With 32-Facility Acquisition

PACS Group announced definitive agreements to acquire operations of 32 skilled nursing facilities across Florida with 4,049 licensed beds from Omega Healthcare Investors subsidiaries. The transaction, expected to close in Q4 2026, expands PACS's presence in the high-growth post-acute care market and establishes a statewide network in Florida. The acquisition complements PACS's existing Southern footprint across Texas, South Carolina, Tennessee, and Kentucky.

PB or CFR: Which Is the Better Value Stock Right Now?

In a comparison of two Banks - Southwest sector stocks, Prosperity Bancshares (PB) emerges as the more attractive option for value investors compared to Cullen/Frost Bankers (CFR). PB holds a Zacks Rank of #2 (Buy) versus CFR's #3 (Hold), and demonstrates superior valuation metrics including a lower forward P/E ratio of 11.25 versus CFR's 14.90, a better PEG ratio of 0.79 versus 2.49, and a lower P/B ratio of 0.88 versus 2.26. PB also earned a Value grade of B compared to CFR's C grade.

Why Lockheed Martin Stock Popped Today

UBS upgraded Lockheed Martin to buy, citing strong growth prospects from its F-35 fighter jet franchise and missile sales. With a book-to-bill ratio of 3.2x, UBS forecasts 9% annual sales growth and double-digit earnings growth over the next 2-3 years. At 19.2x earnings and less than 14x free cash flow with a 2.6% dividend yield, analysts see Lockheed as an attractive defense stock with earnings growth expected to exceed 19% over five years.

2 Nuclear Energy Stocks to Buy Before 2026 Ends

The nuclear energy market is experiencing a resurgence driven by AI infrastructure demands, decarbonization initiatives, and safer technologies. The article recommends two stocks: Uranium Energy (UEC), which benefits from rising uranium prices through spot-price sales, and BWX Technologies (BWXT), a diversified nuclear component manufacturer with a strong defense sector presence and growing commercial backlog.

Is Alphabet Stock Undervalued?

Alphabet's P/E ratio of 17x appears undervalued compared to the S&P 500's 25x, but this is misleading due to one-time investment gains from SpaceX holdings artificially boosting earnings. Using alternative valuation metrics like operating profit and operating cash flow, Alphabet trades at average to above-average historical levels. The stock is a reasonable investment but not a compelling buying opportunity like it was in April 2025.

NuScale Power Stock Broke Out in August. Is It a Buy?

NuScale Power gained 10.1% in August following a brutal July, driven by announcements of AI tools for nuclear design and strong demand from data centers seeking carbon-free energy. However, the company reported a 99% revenue decline in Q2 to just $75,000, continues to burn cash, and remains years away from deploying its first reactor. Commercial execution remains unproven, with the stock trading on speculation pending signed power purchase agreements.

Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?

Novo Nordisk's stock has declined 66% from its 2024 high and now trades at attractive valuations compared to historical averages. While the company lost its GLP-1 weight-loss drug market lead to Eli Lilly, it is attempting a comeback through a new GLP-1 pill and a volume-driven pricing strategy. Despite significant uncertainty around its competitive position and business transition, the stock's low valuation and 3.7% dividend yield may appeal to value and dividend investors.

Kaplan Fox Encourages Wix.com Ltd. (NASDAQ: WIX) Investors with Significant Losses to Contact the Firm Before September 22, 2026

Kaplan Fox & Kilsheimer LLP has filed class action lawsuits against Wix.com, Hertz Global Holdings, and Hims & Hers Health on behalf of investors who suffered losses. The Wix lawsuit covers investors from February 19, 2025 to May 12, 2026, alleging the company misrepresented its AI capabilities while costs accelerated. Wix's stock fell 27.1% following disappointing Q1 2026 results. Investors with losses are encouraged to contact the firm before respective deadlines.

Deadline Alert: Simply Good Foods Company (SMPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Simply Good Foods Company (SMPL) faces a class action securities fraud lawsuit alleging the company made false statements about its OWYN acquisition between October 2024 and April 2026. The lawsuit claims management failed to disclose product quality issues from a new pea protein supplier, loss of key personnel, excessive promotional activities, and severe integration problems that caused OWYN sales to contract 17% year-over-year. The stock declined significantly following earnings announcements in October 2025 and April 2026, with a $187 million impairment charge taken against OWYN assets.

SKY BLUE CINEMATIX - ENTERTAINMENT - BRAND INTEGRATION : Two Films. One Global Partnership.

Sky Blue Cinematix has been appointed as the exclusive worldwide brand-integration partner for two upcoming feature films from Tested Films: the action thriller 'Habeas Corpus' and the neo-noir romantic mystery 'Blurred', both directed by Ben Cookson. The partnership will connect international brands with these theatrical productions through in-film integration across all territories.

Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight

The chronic myeloid leukemia (CML) clinical trial pipeline shows robust activity with 25+ pharmaceutical companies developing 25+ pipeline drugs. Key players including Merck, Enliven Therapeutics, ImmunoForge, and others are advancing promising therapies like TERN-701, ELVN-001, and KF1601 across various clinical stages. The market is evolving from established tyrosine kinase inhibitors toward newer selective agents targeting resistance, intolerance, and treatment-free remission.

BUREAU VERITAS – Nouvelle émission obligataire de 700 millions d'euros à échéance septembre 2027 - final terms (en anglais)

Bureau Veritas has successfully completed a bond issuance of EUR 700 million with maturity in September 2034. The company also disclosed its number of shares and voting rights as of August 31, 2026.

Taiwan Semiconductor Just Set a New Company Record. A New All-Time High Stock Price Is Coming

Taiwan Semiconductor Manufacturing (TSMC) has reached new all-time highs in gross profit margins, driven by its dominant position in AI chip fabrication. With over 70% of global chip foundry revenue and strong pricing power, the company's improved profitability suggests the stock could reach new all-time highs, as current valuations don't yet reflect the premium margins of this improved business.

BUREAU VERITAS - EUR 700 million new bond issue maturity September 2034 - final terms

Bureau Veritas successfully completed a EUR 700 million bond issuance with maturity in September 2034. The company also reported its number of shares and voting rights as of August 31, 2026, in compliance with French financial regulations.

Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now

While Pfizer offers a higher dividend yield of 6.1%, AbbVie is positioned as the superior long-term dividend stock. AbbVie has demonstrated stronger revenue growth (138% over a decade vs. Pfizer's 18%), is a Dividend King with 53 consecutive years of dividend increases, and has successfully navigated the loss of Humira exclusivity through home-grown replacements Skyrizi and Rinvoq. In contrast, Pfizer faces significant patent cliff exposure between 2026-2028 with $17-18 billion in annual revenue at risk from generic competition.

S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today

Crude near $98 pushes the 10-year Treasury yield above 4.8% for the first time since 2023, hammering the Dow as traders price a Fed rate hike next week.

OS Therapies Reports Strong Survival Data for Bone Cancer Treatment

OS Therapies (NYSE: OSTX) interim Phase 2b trial data shows a 71.2% 3-year overall survival rate for OST-HER2 vs. 45.8% for controls.

Google Collaborates With Nevoya, Center For Green Market Activation To Deploy 25 Electric Semi Trucks Between Houston, Dallas Route